US 12,091,457 B2
Use for preventing and treating myeloid-derived suppressor cell-related diseases
Soseul Kim, Seoul (KR); Jeong Won Hong, Seoul (KR); Gil Yong Ji, Seoul (KR); Sangsoon Yoon, Seoul (KR); and Hyung-Geun Song, Cheongju-si (KR)
Assigned to KUMHO HT, INC., Gwangju (KR)
Appl. No. 17/052,591
Filed by Kumho HT, Inc., Gwangju (KR)
PCT Filed May 14, 2019, PCT No. PCT/KR2019/006007
§ 371(c)(1), (2) Date Nov. 3, 2020,
PCT Pub. No. WO2019/221574, PCT Pub. Date Nov. 21, 2019.
Claims priority of application No. 10-2018-0054977 (KR), filed on May 14, 2018; and application No. 10-2019-0055950 (KR), filed on May 13, 2019.
Prior Publication US 2022/0119518 A1, Apr. 21, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 37/00 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2803 (2013.01) [A61P 35/00 (2018.01); A61K 2039/505 (2013.01)] 22 Claims
 
1. An immune-enhancing agent comprising an antibody or an antigen-binding fragment thereof specifically binding to CD66c (Cluster of Differentiation 66c) which is expressed in a myeloid-derived suppressor cell (MDSC),
wherein the antibody or antigen-binding fragment thereof comprises the following complementarity determining regions (CDRs):
CDR-H1 comprising an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 9,
CDR-H2 comprising an amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 10,
CDR-H3 comprising an amino acid sequence of SEQ ID NO: 3,
CDR-L1 comprising an amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 11 or SEQ ID NO: 12,
CDR-L2 comprising an amino acid sequence of SEQ ID NO: 5 and
CDR-L3 comprising an amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 13,
on the proviso that the antibody comprising CDRs consisting of amino acid sequences of SEQ ID NOs: 1, 2, 3, 4, 5, and 6 is not included.